IPO - Profile

Summary

We are a biopharmaceutical company developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically-relevant proteins. We have developed a proprietary protein degradation platform, called QuEEN, that enables us to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates that are designed to eliminate therapeutically-relevant proteins in a highly selective manner. We believe our small molecule MGDs may give us significant advantages over existing therapeutic modalities, including other protein degradation approaches, by allowing us to target proteins that More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$19.00 11,700,000 Positive High 33.39%

Offering Team

  • Legal counsel
  • Goodwin Procter LLP
  • Auditors
  • Deloitte & Touche LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 23 Jun, 2021

Offer 24 Jun, 2021

Look Ahead

Lock Up Expiry Dec 24, 2021

IPO Terms

Offer Price $19.00
Offer Size 11M

Market Sentiments

Stock Price